Cure8 research brief
If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears feasible, with some patients needing dose adjustments or returning to IV if response is lost.
Adult IBD patients on vedolizumab (or considering a switch to subcutaneous vedolizumab), their caregivers, and gastroenterology clinicians managing biologic therapy.
A national prospective cohort in France tracked patients with UC or CD who were in clinical remission when they switched from IV vedolizumab to the subcutaneous formulation between 2022–2024. After one year, 84% remained on SC‑VDZ.
About 10% had dose escalation; a small portion stopped due to loss of response, and several were switched back to IV with reported success for most. The researchers measured vedolizumab drug levels and found similar concentrations in patients who stayed on SC‑VDZ and those who did not.
Adverse events were common but mostly mild; injection‑site reactions and infections were the leading reasons for discontinuation in some patients. This report summarizes the study abstract and does not replace reading the full paper for details such as inclusion criteria, statistical methods, or subgroup analyses.
This summary is based on the article abstract. Details such as patient selection, definitions of remission, exact safety grading, and longer-term outcomes require reading the full paper. Drug level comparisons reported here are from the study abstract; consult the full text for assay methods and timing.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...
